Hutchinson-gilford Progeria Syndrome

• EMA approval · 2026-04-07
  EMA Authorised: Zokinvy (Lonafarnib) — TMC Pharma (EU) Limited

  The European Medicines Agency authorised Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome and laminopathies in the European Uni…

• FDA approval · 2024-03-21
  FDA Approved: ZOKINVY — Supplemental Application (Sentynl Therapeutics, Inc.)

  FDA approved a supplemental application for ZOKINVY (lonafarnib) from Sentynl Therapeutics, Inc. under NDA 213969. The action approves chang…

• EMA approval · 2022-05-20
  First treatment for children with Progeria or progeroid like syndromes (rare premature aging syndromes)

  EMA announces first treatment for children with Progeria and other progeroid syndromes, offering a targeted option for these rare premature …

• FDA approval · 2020-11-20
  FDA Approved: ZOKINVY — Original Application (Sentynl Therapeutics, Inc.)

  The FDA approved Zokinvy (lonafarnib) from Sentynl Therapeutics for Hutchinson-Gilford Progeria Syndrome and processing-deficient progeroid …